Michael Montoya, MD
Family Medicine · Albuquerque, NMNPI 1215046545
Payments from drug & device makers
Across 438 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$686
- Novo Nordisk$643
- AbbVie$508
- Pfizer$491
- Boehringer Ingelheim$489
- plus $3K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $1,455 |
| Lilly USA, LLC | 56 | $686 |
| Novo Nordisk | 40 | $643 |
| AbbVie(2 entities) | 41 | $508 |
| Pfizer | 44 | $491 |
| Boehringer Ingelheim | 28 | $489 |
| Merck | 33 | $408 |
| Sanofi-aventis U.S. LLC | 16 | $268 |
| Johnson & Johnson | 20 | $264 |
| Exact Sciences | 11 | $253 |
| Amgen | 11 | $208 |
| Amarin Pharma, Inc. | 13 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $151 |
| Teva Pharmaceuticals USA, Inc. | 8 | $143 |
| Nestle Healthcare Nutrition Inc. | 8 | $134 |
| Novartis | 8 | $121 |
| Bayer | 4 | $110 |
| BD | 2 | $94 |
| Biohaven Pharmaceuticals, Inc. | 4 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Dexcom, Inc. | 3 | $66 |
| Abbott | 2 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $39 |
| Upsher-smith Laboratories LLC | 2 | $37 |
| Organon | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| GRT US Holding, Inc. | 2 | $32 |
| GSK | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Nevro Corp. | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| MDD US Operations, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Medtronic | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Metacel Pharmaceuticals LLC | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$7,293 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Albuquerque
- Quito CarrAlbuquerque$10.4M
- Satkirin KhalsaAlbuquerque$5.8M
- Ellen KimAlbuquerque$2.2M
- Sally FisherAlbuquerque$1.8M
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Yvonne Vanarsdale-ImaniAlbuquerque$7K
- Donald OrtizAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.